Financial Performance - The Group's revenue for the Relevant Period was $6.8 million, representing a slight decrease of $0.2 million or 3.3% compared to $7.1 million in the Previous Period[18]. - The Group's profit for the Relevant Period was $173,000, down from a profit of $506,000 in the Previous Period[19]. - Gross profit for the Relevant Period was $2.3 million, compared to $2.5 million in the Previous Period[20]. - Profit before taxation was $267,000, down from $596,000 in the Previous Period[20]. - Earnings per share for the Relevant Period were 0.02 cents, compared to 0.06 cents in the Previous Period[20]. - Total revenue for 2025H1 was $6,837,000, a decrease of 3.25% from $7,067,000 in 2024H1[39]. - Segment profit for tissue products was $2,048,000, down 5.52% from $2,168,000 in 2024H1[39]. - Revenue from external customers for hygiene-related products was $382,000, a decline of 14.36% from $446,000 in 2024H1[39]. - The Group's consolidated profit before taxation for 2025H1 was $267,000, a decrease of 55.32% compared to $596,000 in 2024H1[42]. - Basic earnings per share for 2025H1 was 0.02 cents, down from 0.06 cents in 2024H1[48]. - Net profit attributable to shareholders for the period was $173,000, down from $506,000 in the same period last year[83]. - Sales of hygiene-related products decreased by $64,000, representing a decrease of 14.3%[84]. Expenses and Costs - Selling and distribution expenses increased to $1.046 million from $0.914 million in the Previous Period[20]. - Administrative expenses remained relatively stable at $1.033 million compared to $1.021 million in the Previous Period[20]. - The Group's cost of sales for the Relevant Period was $4.5 million, slightly down from $4.6 million in the Previous Period[20]. - Total unallocated expenses increased to $2,079,000 in 2025H1 from $1,935,000 in 2024H1[42]. - The cost of inventories for 2025H1 was $3,905,000, a decrease from $4,152,000 in 2024H1[43]. - Selling and distribution expenses increased from $0.9 million to $1.0 million, an increase of 14.4% due to inflation and changes in the sales commission structure[75]. Assets and Liabilities - Total assets decreased slightly to $21,695,000 as of March 31, 2025, from $21,785,000 on September 30, 2024, representing a decline of approximately 0.4%[21]. - Total liabilities decreased to $3,331,000 as of March 31, 2025, down from $3,594,000, representing a reduction of about 7.3%[21]. - Trade and other receivables increased to $2,381,000 as of March 31, 2025, up from $2,273,000, indicating a rise of about 4.8%[21]. - Trade receivables as of March 31, 2025, were $2,187,000, slightly up from $2,183,000 as of September 30, 2024[52]. - Trade payables as of March 31, 2025, were $457,000, down from $546,000 as of September 30, 2024[63]. - Cash and cash equivalents at the end of the period rose to $3,682,000, compared to $2,868,000 at the end of the first half of 2024, marking an increase of approximately 28.4%[23]. - The Group had cash and bank balances of $3.7 million as of March 31, 2025, up from $3.5 million as of September 30, 2024[87]. Shareholder Information - The Board has resolved not to declare the payment of dividend for the Relevant Period[18]. - The Group has not declared any dividends for 2025H1, consistent with 2024H1[49]. - Mr. Chua Liang Sie holds a long position of 552,000,000 shares, representing 69% of the total issued shares[116]. - Mr. Chua Liang Chui also holds a long position of 552,000,000 shares, representing 69% of the total issued shares[116]. - YJH Group Limited is approximately 82.76% owned by Mr. Chua Liang Sie and 17.24% by Mr. Chua Liang Chui[117]. - The company’s retained earnings increased to $4,318,000 as of March 31, 2025, compared to $3,916,000, reflecting a growth of approximately 10.3%[22]. Corporate Governance and Compliance - The unaudited financial statements are prepared in accordance with International Accounting Standard 34, ensuring compliance with applicable regulations[29]. - The Company has adopted the Required Standard of Dealings, and all Directors confirmed compliance during the Relevant Period[129]. - The Audit Committee consists of three independent non-executive Directors, who have reviewed the unaudited condensed consolidated financial statements for the Relevant Period[140]. - The Company has adopted and complied with the Corporate Governance Code, with a noted deviation regarding the roles of Chairman and Chief Executive Officer being held by the same individual[139]. - The company maintains compliance with the GEM Listing Rules regarding the disclosure of interests and positions[120]. Future Outlook and Strategy - The company is optimistic about industry growth in Singapore, emphasizing the necessity of tissue products[67][68]. - The company aims to achieve sustainable growth and greater returns for shareholders through continuous evaluation of development opportunities[68]. - Future outlook indicates a projected revenue growth of 15% for FY2025 compared to FY2024[149]. - The company plans to invest in new technology for tissue production, aiming to increase efficiency by 20%[150]. - The company is exploring potential acquisitions to strengthen its supply chain and distribution network[150]. - New product lines are expected to launch in Q3 2024, targeting both domestic and international markets[149]. - Ongoing research and development efforts are focused on sustainable materials, with a target of 30% recycled content in products by 2025[149]. - The company aims to enhance shareholder value through strategic initiatives and operational improvements[150].
日光控股(08451) - 2025 - 中期业绩